LAMC2, LAMB3, and TSPAN1 expression in pancreatic ductal adenocarcinoma (PDAC)
Description
Pancreatic ductal adenocarcinoma (PDAC) is an extremely lethal cancer, with a 5-year survival rate under 10%. It is often diagnosed late, contributing to poor prognosis and limited treatment options. To find new gene targets for PDAC, we screened the Genomics Analysis and Visualization Platform (R2) and identified three genes with high expression in PDAC patients. These genes were: Laminin Subunit Gamma 2 (LAMC2), Laminin Subunit Beta 3 (LAMB3), and Tetraspanin 1 (TSPAN1). Using a mixed PDAC (n=45)/normal pancreas (n=45) human dataset, we compared the gene expression for LAMC2, LAMB3, and TSPAN1 between normal and cancerous tissues. Next, a correlation between the expression of LAMC2/LAMB3, LAMC2/TSPAN1, and LAMB3/TSPAN1 was calculated utilizing the Pearson coefficient of determination (R²) function. An R² value above 0.80 was accepted as a strong correlation between two variables. Lastly, Kaplan Meier survival curves were used to determine the correlation between each gene expression and overall patient survival. Results showed that LAMC2, LAMB3, and TSPAN1 expressions were significantly elevated in PDAC compared to normal pancreas. Each two gene correlations were statistically significant, with the R² values obtained for LAMC2 and LAMB3, LAMC2 and TSPAN1, and LAMB3 and TSPAN1 being 0.92, 0.80, and 0,81, respectively. Patients expressing high levels of these genes had overall poorer survival compared with patients with low expression of the same genes. The findings from this study may contribute to the expanding body of knowledge on PDAC, supporting the ongoing efforts of scientists and healthcare professionals to combat this aggressive disease.
Citation Information
Naraharisetti, Soujanya and Ananieva-Stoyanova, Elitsa, "LAMC2, LAMB3, and TSPAN1 expression in pancreatic ductal adenocarcinoma (PDAC)" (2026). Office of Research DMU Research Symposium. 87.
https://digitalcommons.dmu.edu/researchsymposium/2025rs/2025abstracts/87
LAMC2, LAMB3, and TSPAN1 expression in pancreatic ductal adenocarcinoma (PDAC)
Pancreatic ductal adenocarcinoma (PDAC) is an extremely lethal cancer, with a 5-year survival rate under 10%. It is often diagnosed late, contributing to poor prognosis and limited treatment options. To find new gene targets for PDAC, we screened the Genomics Analysis and Visualization Platform (R2) and identified three genes with high expression in PDAC patients. These genes were: Laminin Subunit Gamma 2 (LAMC2), Laminin Subunit Beta 3 (LAMB3), and Tetraspanin 1 (TSPAN1). Using a mixed PDAC (n=45)/normal pancreas (n=45) human dataset, we compared the gene expression for LAMC2, LAMB3, and TSPAN1 between normal and cancerous tissues. Next, a correlation between the expression of LAMC2/LAMB3, LAMC2/TSPAN1, and LAMB3/TSPAN1 was calculated utilizing the Pearson coefficient of determination (R²) function. An R² value above 0.80 was accepted as a strong correlation between two variables. Lastly, Kaplan Meier survival curves were used to determine the correlation between each gene expression and overall patient survival. Results showed that LAMC2, LAMB3, and TSPAN1 expressions were significantly elevated in PDAC compared to normal pancreas. Each two gene correlations were statistically significant, with the R² values obtained for LAMC2 and LAMB3, LAMC2 and TSPAN1, and LAMB3 and TSPAN1 being 0.92, 0.80, and 0,81, respectively. Patients expressing high levels of these genes had overall poorer survival compared with patients with low expression of the same genes. The findings from this study may contribute to the expanding body of knowledge on PDAC, supporting the ongoing efforts of scientists and healthcare professionals to combat this aggressive disease.
